We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Vazegepant

News List

Biohaven to Proceed with Intranasal Vazegepant Trial for COVID-19 Lung Inflammation americanpharmaceuticalreview
April 14, 2020
Biohaven Pharmaceutical announced it submitted Pre-IND/IND material to the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 study of vazegepant.
Biohaven to Advance Vazegepant into Phase 3 for Acute Treatment of Migraine americanpharmaceuticalreview
March 26, 2020
Biohaven Pharmaceutical announced a successful end of Phase 2 clinical and nonclinical interaction with the U.S. Food and Drug Administration (FDA) for intranasal vazegepant ...
Biohaven Achieves Positive Topline Results in Migraine Study americanpharmaceuticalreview
December 18, 2019
Biohaven Pharmaceutical announced positive topline results from its randomized, dose ranging, placebo controlled, pivotal Phase 2/3 clinical trial evaluating the efficacy and tolerability ...